Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 151 people across six groups, each receiving different sequences of treatments — a placebo (inactive treatment), a 5 microgram dose of olodaterol (Olo 5 mcg), and a 10 microgram dose of olodaterol (Olo 10 mcg) — in varying orders over three treatment periods. The trial was designed as a "crossover" study, meaning every participant received all three treatments at different times, just in a different order. Between 20 and 25 people in each group completed the full study. The main thing being measured was how long participants could keep exercising on a stationary bike at a set level of effort after six weeks on each treatment. The reported data shows that after six weeks, the average exercise endurance time — measured in seconds — was approximately 370 seconds for the placebo group, around 422 seconds for those on the 5 mcg olodaterol dose, and around 421 seconds for those on the 10 mcg dose. For the secondary measures, the reported data shows that a lung capacity measurement called "inspiratory capacity" (how much air a person can breathe in) was slightly higher in both olodaterol groups compared to placebo, at several points during the exercise test. Breathing discomfort, rated on a scale of 0 (nothing at all) to 10 (maximum discomfort) during exercise, was reported as approximately 5.9 for placebo, 5.1 for the 5 mcg dose, and 5.2 for the 10 mcg dose. Before exercise began, discomfort scores were low across all groups (all under 0.3 out of 10). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27383762) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 COPD Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have agreed to take part by signing a consent form before the study begins.
- You have been diagnosed with chronic obstructive pulmonary disease (COPD) and your breathing test results meet certain specific measurements (confirm with trial site).
- You are between 40 and 75 years old (male or female).
- You are a current or former smoker with at least a 10 pack-year smoking history (roughly, smoking one pack a day for 10 years, or equivalent).
- You are able to do breathing tests, multiple exercise tests, and keep records as required by the study.
- You are able to use an inhaler device correctly, including both a standard metered-dose inhaler and a Respimat inhaler.
Who may not be able to join:
- You have significant abnormal results in blood or urine tests at the start of the study, including certain liver or kidney markers that are more than twice the normal level (confirm with trial site).
- You have a history of asthma, or your blood shows a high level of a certain type of immune cell called eosinophils.
- You have an overactive thyroid or a resting heart rate that is regularly above 100 beats per minute.
- You have had a heart attack in the past year, a serious heart rhythm problem, a hospital stay for heart failure in the past year, active tuberculosis, certain cancers treated within the last five years, severe lung blockage, cystic fibrosis, significant bronchiectasis, serious alcohol or drug misuse, or a condition that makes exercise unsafe.
- You have previously had surgery to remove part of a lung.
- You are currently taking certain oral steroid or oral beta-adrenergic medications at unstable doses or at doses above a certain level (confirm with trial site).
- You regularly use supplemental oxygen during the day for more than one hour per day.
- You have completed a pulmonary rehabilitation programme in the six weeks before the study starts, or you are currently enrolled in one.
- Your ability to exercise is limited by a reason other than tiredness or breathlessness during activity.
- You are pregnant or currently breastfeeding.
- You are a woman who could become pregnant and are not using two forms of birth control at the same time (one barrier method and one non-barrier method).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Boehringer Ingelheim, Boehringer Ingelheim
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Adjusted Mean Endurance Time After 6 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.